Short answer
STAAR SURGICAL CO (STAA) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results released for quarter ended July 3, 2026.
STAAR SURGICAL CO 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results released for quarter ended July 3, 2026
- Press release furnished as Exhibit 99.1 contains the reported financial figures and operating details
Item 7.01 · Regulation FD Disclosure
- Management conference call scheduled August 12, 2026 at 5:30 p.m. Eastern
- Discussion covers quarterly results for the quarter ended August 12, 2026
- CEO and CFO participation signals direct management commentary on results
- Disclosure furnished under Regulation FD, not subject to Exchange Act Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 net sales $93.5M, up 111% YoY, driven by China sales of $52.3M and EVO+ adoption
- China represented over 50% of revenue, with market-share gains but heightened geographic concentration risk
- Net income $8.1M versus $(16.8)M loss; GAAP EPS $0.16 versus $(0.34) prior year
- Adjusted EBITDA $20.0M versus $(14.8)M, indicating substantial operating leverage despite ERP investment costs
- Cash and investments $181.5M, up from $163.9M; no outstanding debt supports continued investment in production and innovation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STAAR SURGICAL CO 8-K filings
Get the next STAA 8-K as it lands
Follow STAA for push alerts, or ask the research agent what this filing means.